LXEO
Lexeo Therapeutics·NASDAQ
--
--(--)
--
--(--)
11.79 / 10
Outperform
Analyst consensus is overwhelmingly bullish: two strong‑buy ratings with 75% and 86% historical win rates. Fund‑flow score 7.59/10 is good; small‑, medium‑ and large‑size inflows are positive, though overall and extra‑large trends are negative, creating mixed liquidity signals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-13
InstitutionChardan Capital
Times predicted7
Historical Win Rate85.7%
What is the analyst consensus for LXEO?
- LXEO holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 11.79/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
